IOVA - Iovance Biotherapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
24.50
-0.21 (-0.85%)
As of 12:48PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close24.71
Open24.66
Bid24.16 x 900
Ask24.21 x 800
Day's Range24.00 - 24.94
52 Week Range7.26 - 26.59
Volume543,423
Avg. Volume1,318,728
Market Cap3.092B
Beta (3Y Monthly)2.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December

    Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. The company is currently conducting pivotal studies in patients with metastatic melanoma and advanced cervical cancer. In addition, the company’s TIL therapies are being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including head and neck and non-small cell lung cancer.

  • GlobeNewswire

    Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 Therapy

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced results of a subgroup analysis of Cohort 2 of the Phase 2 lifileucel metastatic melanoma study C-144-01 in patients who were primary refractory to prior anti-PD-1/L1 therapy. In the subgroup analysis conducted for primary refractory patients in our Cohort 2 of the C-144-01 study, TIL demonstrates excellent efficacy and durability of response thus far.

  • GlobeNewswire

    Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer 34th Annual Meeting

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that new data from Cohort 2 of the ongoing Phase 2 lifileucel metastatic melanoma study (C-144-01) were presented Friday, Nov. 8, 2019, at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting in National Harbor, Maryland (Abstract P865). Median DOR was not reached as assessed by either IRC (range: 1.6+ to 21.2+ months) or investigator (range: 2.2 to 21.2+ months) at 11.3 months median follow up. In addition, based on the most recent data cut from the study, median DOR was not reached as assessed by investigator at 12.8 months of median study follow-up.

  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Investor Conferences in November

    Iovance Biotherapeutics intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer.

  • GlobeNewswire

    Iovance Biotherapeutics Reports Third Quarter and September Year-to-Date 2019 Financial Results

    - Late-breaking abstract at Society for Immunotherapy of Cancer (SITC) meeting to feature Independent Review Committee (IRC) read results from Cohort 2 of C-144-01.

  • GlobeNewswire

    Iovance Biotherapeutics to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Monday, November 4, 2019

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its third quarter 2019 financial results on Monday, November 4, 2019. The live webcast can be accessed under “News & Events” in the Investors section of the Company’s website at www.iovance.com or at the link: https://edge.media-server.com/mmc/p/9ohu47kv. Iovance Biotherapeutics intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers.

  • GlobeNewswire

    Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual Meeting

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that four abstracts highlighting its TIL therapy will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting from November 6-10, 2019 in National Harbor, Maryland. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer.

  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Conferences

    Live and archived webcasts of the Cell & Gene Meeting on the Mesa and 2019 Cantor Global Healthcare Conference presentations will be available in the Investors section of the Iovance website at http://ir.iovance.com. Iovance Biotherapeutics intends to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer.

  • GlobeNewswire

    Iovance Biotherapeutics to Present at Upcoming Investor Conferences in September

    Live and archived webcasts of the presentations will be available by visiting the Investors section of the Iovance Biotherapeutics website at http://ir.iovance.com. Iovance Biotherapeutics intends to commercialize autologous cell therapy products for solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own immune cells to attack cancer cells.

  • GlobeNewswire

    Iovance Biotherapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    - Regulatory submission for LN-145 in advanced cervical cancer expected in the second half of 2020 -- Company to host conference call at 4:30 p.m. EDT today - SAN CARLOS,.

  • GlobeNewswire

    Iovance Biotherapeutics to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1, 2019

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its second quarter 2019 financial results on Thursday, August 1, 2019. Iovance Biotherapeutics intends to commercialize autologous cell therapy products for solid tumors and blood cancers.  Tumor infiltrating lymphocyte (TIL) therapy uses a patient’s own cancer-fighting immune cells to attack solid tumors. TIL are extracted from tumor cells, and once expanded through a proprietary process are infused back into the patient.

  • GlobeNewswire

    Iovance Biotherapeutics Appoints Friedrich Graf Finckenstein, M.D., as Chief Medical Officer

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Friedrich Graf Finckenstein, M.D., as chief medical officer. Dr. Graf Finckenstein brings over 19 years of experience in clinical development and translational research to the company. “We are very pleased to have Dr. Finckenstein join Iovance as we move forward with pivotal studies for lifileucel in metastatic melanoma and LN-145 in metastatic cervical cancer,” said Maria Fardis, Ph.D., president and chief executive officer of Iovance Biotherapeutics.

  • GlobeNewswire

    Iovance Biotherapeutics Provides Cervical Cancer Program Updates Following End of Phase 2 Meeting with U.S. Food and Drug Administration (FDA)

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today provided an update on the regulatory path for LN-145 in advanced cervical cancer. Based on an End of Phase 2 meeting held with the U.S. Food and Drug Administration (FDA), the FDA has acknowledged that the ongoing innovaTIL-04 study of TIL therapy LN-145 may be sufficient to support registration in the treatment of patients with advanced cervical cancer. The study is being enrolled with a prospective definition of objective response rate (ORR) read out by a Blinded Independent Review Committee (BIRC) as the primary endpoint.  In accordance with the FDA’s recommendation, the new version of the protocol will further define the patient population.

  • GlobeNewswire

    Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Athena Countouriotis, M.D., to the company’s Board of Directors, effective June 10, 2019. “Dr. Countouriotis has a long record of successful leadership in oncology drug development, and particular expertise in bringing novel therapies through clinical development,” commented Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics.

  • GlobeNewswire

    Updated Results of Studies in Advanced Cervical Cancer and Melanoma Support Long-Term Efficacy of Iovance Tumor Infiltrating Lymphocyte (TIL) Therapy

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced updated data from studies of TIL therapy LN-145 in patients with advanced cervical cancer and TIL therapy lifileucel in advanced melanoma. At 7.4-month median follow-up in the ongoing study of LN-145 in advanced cervical cancer, an 11 percent complete response rate (CR) was seen.

  • GlobeNewswire

    Iovance Biotherapeutics to Participate in Upcoming Conferences in June

    SAN CARLOS, Calif., May 31, 2019 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on.

  • GlobeNewswire

    Iovance Biotherapeutics Announces New Facility to Support U.S. Production of Tumor Infiltrating Lymphocyte Cell Therapy Products

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it has entered into a lease agreement to build an approximately 136,000 square foot commercial-scale production facility in Philadelphia for commercial and clinical production of autologous TIL products, including its candidate lifileucel. The facility will be designed and built for an ultimate maximum capacity to manufacture TIL products for several thousands of patients annually. The lease agreement and construction of the new Iovance facility at the Navy Yard is expected to ultimately create employment opportunities for several hundred individuals in Philadelphia once at full capacity.

  • GlobeNewswire

    Iovance Biotherapeutics Announces Updates to Tumor Infiltrating Lymphocyte (TIL) Therapy Clinical Programs

    Patients with advanced cervical cancer treated with LN-145 had an objective response rate of 44 percent Patients in Cohort 2 with advanced melanoma treated with lifileucel.

  • GlobeNewswire

    Iovance Biotherapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today reported first quarter 2019 financial results and provided a corporate update. “We have made great progress in recent months in advancing TIL therapy toward commercialization.

  • GlobeNewswire

    Iovance Biotherapeutics to Participate in Upcoming Conferences in May

                A live and archived webcast of the presentation will be available by visiting the Investors section of Iovance Biotherapeutics’ website at http://ir.iovance.com. Iovance Biotherapeutics intends to commercialize lifileucel, an autologous cell therapy product using TIL technology that amplifies the body’s own immune response to eradicate solid tumors or attack blood cancers. The company is currently conducting the pivotal study innovaTIL-01 in patients with metastatic melanoma.

  • GlobeNewswire

    Iovance Biotherapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2019 financial results on Tuesday, May 7, 2019.

  • GlobeNewswire

    Iovance Biotherapeutics to Present New Data from Ongoing Studies of Tumor-Infiltrating Lymphocyte (TIL) Therapy at 2019 American Society of Clinical Oncology (ASCO) Meeting

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that new interim data from Cohort 2 of the innovaTIL-01 (C-144-01) study and data from the ongoing innovaTIL-04 (C-145-04) study will be presented at the American Society of Clinical Oncology (ASCO) annual meeting taking place from May 31 to June 4, 2019, in Chicago.

  • GlobeNewswire

    Iovance Biotherapeutics Announces Clinical Programs Update

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced an update to its clinical programs with TIL therapy in the treatment of cervical cancer and non-small cell lung cancer (NSCLC). The protocol for innovaTIL-04 (C-145-04), the Phase 2 study in cervical cancer, was amended to increase the sample size to 59 and to modify the primary endpoint of Objective Response Rate (ORR) to be determined by a Blinded Independent Review Committee (BIRC).

  • GlobeNewswire

    Iovance Biotherapeutics Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma

    Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that first patient has been dosed in Cohort 4, the pivotal cohort of the innovaTIL-01 (C-144-01) study of lifileucel. Cohort 4 is designed to enroll 75 patients with advanced melanoma. “Dosing of the first patient in Cohort 4, the pivotal arm of our melanoma program, is a significant step toward registration of TIL therapy,” commented Maria Fardis, Ph.D., president and chief executive officer of Iovance.

  • GlobeNewswire

    Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel

    Results from an analysis of the persisting T cell clones circulating 42 days following infusion, as compared to the initial TIL product, demonstrated two phenomena: first, that TIL product from 100 percent of the evaluated patients in Cohort 2 of the innovaTIL-01 trial are persisting in circulation at 42 days post-infusion, and second, that each patient has a unique TIL product with almost no overlap between patients for expanding clones in the human body observed post-infusion. The uniqueness of the clonal profiles associated with response highlights the challenge of identifying a few T cell receptors as mediators of activity and supports using a polyclonal product such as the Iovance bulk TIL to treat high mutational load solid tumors. “Investigation of pharmacokinetics of lifileucel TIL in metastatic melanoma patients demonstrates excellent persistence of lifileucel 42 days post-infusion.